Anesthesia consideration in the era of perioperative immunotherapy for non-small cell lung cancer
10.12354/j.issn.1000-8179.2023.20230845
- VernacularTitle:非小细胞肺癌围手术期免疫治疗时代的麻醉思考
- Author:
Weiran LIU
1
;
Bin ZHANG
Author Information
1. 天津医科大学肿瘤医院麻醉科,国家恶性肿瘤临床医学研究中心,天津市"肿瘤防治"重点实验室,天津市恶性肿瘤临床医学研究中心 天津市 300060
- Keywords:
non-small cell lung cancer(NSCLC);
perioperative period;
anesthesia;
immunotherapy;
prognosis
- From:
Chinese Journal of Clinical Oncology
2023;50(21):1110-1114
- CountryChina
- Language:Chinese
-
Abstract:
With the advent of perioperative immunotherapy for non-small cell lung cancer(NSCLC),the management of anesthesia in thoracic surgery has become challenging.Different choices for anesthesia modalities and drugs affect immune function,tumor growth,and metastasis.Cancer immunotherapy with immune checkpoint inhibitors activates antitumor immunity,affecting local and systemic immune response.Anesthesia and immunotherapy may cause unpredictable interactions.This review examines the impact of anesthetic modalities and pharmaceuticals along with immunotherapy on the immune status and prognosis of NSCLC,offering new insights for their perioperative management in patients with NSCLC.
